Edition:
United Kingdom

Kyowa Hakko Kirin Co Ltd (4151.T)

4151.T on Tokyo Stock Exchange

2,031JPY
7:00am BST
Change (% chg)

¥5 (+0.25%)
Prev Close
¥2,026
Open
¥2,047
Day's High
¥2,067
Day's Low
¥2,030
Volume
717,500
Avg. Vol
1,164,745
52-wk High
¥2,462
52-wk Low
¥1,894

Latest Key Developments (Source: Significant Developments)

Kyowa Hakko Kirin Buys Back 10.7 Million Shares For 22.59 Billion Yen Before Market Open Weds
Wednesday, 6 Feb 2019 

Feb 6 (Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T>::BOUGHT BACK 10.7 MILLION SHARES FOR 22.59 BILLION YEN BEFORE MARKET OPEN WEDS.  Full Article

Hisamitsu Pharmaceutical Signs Agreement With Kyowa Hakko Kirin For Parkinson's Disease Treatment Hisamitsu Is Developing
Tuesday, 5 Feb 2019 

Feb 5 (Reuters) - Hisamitsu Pharmaceutical Co Inc <4530.T>::SIGNED SALES AGREEMENT WITH KYOWA HAKKO KIRIN FOR PARKINSON'S DISEASE TREATMENT HISAMITSU IS DEVELOPING.KYOWA HAKKO KIRIN WILL SELL ITS PARKINSON'S DISEASE TREATMENT IN JAPAN ONCE ITS APPLICATION IS APPROVED.EXPECTS ITS APPLICATION FOR MANUFACTURE AND SALES WILL BE APPROVED BY FEB 2020.  Full Article

GSK, Kyowa Hakko Kirin Sign Commercialisation Deal In Japan For Daprodustat
Thursday, 22 Nov 2018 

Nov 22 (Reuters) - GlaxoSmithKline Plc ::GSK AND KYOWA HAKKO KIRIN SIGN STRATEGIC COMMERCIALISATION DEAL IN JAPAN FOR DAPRODUSTAT.  Full Article

Kyowa Kirin Announces Mogamulizumab Received Positive CHMP Opinion For Treatment Of Mycosis Fungoides And Sézary Syndrome
Friday, 21 Sep 2018 

Sept 21 (Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T>::KYOWA KIRIN ANNOUNCES MOGAMULIZUMAB RECEIVED POSITIVE CHMP OPINION FOR THE TREATMENT OF MYCOSIS FUNGOIDES AND SÉZARY SYNDROME.KYOWA HAKKO KIRIN - IF MOGAMULIZUMAB APPROVED, KYOWA KIRIN INTERNATIONAL TO BE RESPONSIBLE FOR COMMERCIALIZING MOGAMULIZUMAB IN EUROPE.  Full Article

FDA Approves Poteligeo Injection For Treatment Of Mycosis Fungoides And Sézary Syndrome
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - U.S. Food and Drug Administration:U.S. FDA - APPROVED POTELIGEO INJECTION FOR TREATING ADULTS WITH RELAPSED/REFRACTORY MYCOSIS FUNGOIDES OR SÉZARY SYNDROME AFTER AT LEAST 1 PRIOR SYSTEMIC THERAPY.U.S. FDA SAYS GRANTED APPROVAL FOR TREATMENT FOR TWO RARE TYPES OF NON-HODGKIN LYMPHOMA TO KYOWA KIRIN, INC.  Full Article

Kyowa Kirin Announces FDA Approval Of Poteligeo For Treatment Of Mycosis Fungoides & Sézary Syndrome
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T>::KYOWA KIRIN ANNOUNCES FDA APPROVAL OF POTELIGEO® (MOGAMULIZUMAB-KPKC) FOR THE TREATMENT OF MYCOSIS FUNGOIDES AND SÉZARY SYNDROME.KYOWA HAKKO KIRIN SAYS KYOWA KIRIN INTERNATIONAL PLC WILL BE RESPONSIBLE FOR COMMERCIALIZING POTELIGEO IN U.S. & THIS IS PLANNED TO COMMENCE IN Q4 2018.  Full Article

Kyowa Hakko Kirin sells 66.6 pct stake in unit Kyowa Medex
Thursday, 4 Jan 2018 

Jan 4(Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T>:Says it sold 66.6 percent stake in wholly owned unit Kyowa Medex Co., Ltd., to Hitachi Chemical Company, Ltd <<<4217.T>>>, on Jan. 4 .  Full Article

Kyowa Hakko Kirin says change of chairman and president
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T> ::Says it appoints current president and CEO Nobuo Hanai as new chairman and CEO, Masashi Miyamoto as new president .Changes will be effective on the day of ordinary general meeting of shareholders scheduled in March 2018.  Full Article

Reata Pharmaceuticals- Entered Third Supplement To Exclusive License & Supply Agreement With Kyowa Hakko
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T>::REATA PHARMACEUTICALS-ON DEC 7 CO ENTERED THIRD SUPPLEMENT TO EXCLUSIVE LICENSE & SUPPLY AGREEMENT, BY & BETWEEN CO, KYOWA HAKKO KIRIN CO LTD (KHK).REATA SAYS THIRD SUPPLEMENT ALLOWS CO TO BEGIN PORTION OF PHASE 3 CLINICAL STUDY OF RTA 402 IN FIELD OF ALPORT SYNDROME IN JAPAN - SEC FILING.REATA PHARMACEUTICALS - ON DEC 7 CO ENTERED FOURTH SUPPLEMENT TO EXCLUSIVE LICENSE & SUPPLY AGREEMENT, BY & BETWEEN CO & KHK.  Full Article

Kyowa Hakko Kirin Announces FDA Acceptance For Filing And Priority Review Designation Of Mogamulizumab's Biologics License Application
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T>::KYOWA HAKKO KIRIN ANNOUNCES FDA ACCEPTANCE FOR FILING AND PRIORITY REVIEW DESIGNATION OF MOGAMULIZUMAB'S BIOLOGICS LICENSE APPLICATION.  Full Article